Donepezil Tablet
Product Images NDC 31722-738

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Donepezil (NDC 31722-738). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Address1 (Address1)

FDA Label Image

Address2 (Address2)

FDA Label Image

Donepezil10mg30s (Donepezil10mg30s)

Donepezil Hydrochloride Tablets USP 10 mg oral tablets package label by Camber Pharmaceuticals, Inc. The label shows the NDC 31722-738-30, a package count of 30 tablets, storage instructions, and manufacturer details including Hetero Labs Limited India as the producer.*

FDA Label Image

Donepezil10mgcarton (Donepezil10mgcarton)

Packaging label for Donepezil Hydrochloride Tablets USP 10 mg by Camber Pharmaceuticals, Inc. The label indicates 100 unit dose tablets in a 10 x 10 count. It includes storage instructions, dosage form as film-coated oral tablets, and directs to see package insert for full prescribing information. Manufactured by Camber Pharmaceuticals, Inc., and by Hetero Labs Limited, India.*

FDA Label Image

Donepezil10mgfoil (Donepezil10mgfoil)

Packaging label for Donepezil Hydrochloride Tablet, USP 10 mg, by Camber Pharmaceuticals, Inc., manufactured by Hetero Labs Limited. The label shows multiple barcode sections with product name, strength, dosage form, labeler, manufacturer details, and NDC 31722-738-31.*

FDA Label Image

Donepezil5mg30s (Donepezil5mg30s)

Donepezil Hydrochloride Tablets, USP 5 mg oral tablets label by Camber Pharmaceuticals, Inc. The label indicates a 30 tablet bottle, prescription only, with instructions for storage, dispensing, and manufacturing details. The label includes barcodes, the NDC number 31722-737-30, and batch coding area.*

FDA Label Image

Donepezil5mgcarton (Donepezil5mgcarton)

Packaging label for Donepezil Hydrochloride Tablets USP 5 mg, oral tablets supplied in unit dose packs of 100 (10 x 10). Manufactured for Camber Pharmaceuticals, Inc., Piscataway, NJ, and by Hetero Labs Limited in India. The label includes dosage strength, NDC 31722-737-31, storage instructions, and pharmacist dispensing information.*

FDA Label Image

Donepezil5mgfoil (Donepezil5mgfoil)

Packaging label for Donepezil Hydrochloride Tablet, USP 5 mg, manufactured by Camber Pharmaceuticals, Inc., with text repeating and a barcode visible. The label includes the NDC number 31722-737-31 and mentions HETERO as the manufacturing partner.*

FDA Label Image

Donepezilfigure10 (Donepezilfigure10)

A line graph comparing the cumulative percentage of patients over ADCS-ADL change from baseline for Donepezil hydrochloride 10 mg/day and placebo groups. The x-axis shows ADCS-ADL change from baseline, and the y-axis shows cumulative percentage of patients, illustrating treatment response distribution.*

FDA Label Image

Donepezilfigure8 (Donepezilfigure8)

A cumulative percentage of patients graph comparing Donepezil hydrochloride 10 mg/day and placebo, plotting percentage of patients against SIB change from baseline. The graph shows patient response distribution for both treatment groups with distinct curves.*

FDA Label Image

Figure1 (Figure1)

A line plot graph showing ADAS-cog change from baseline over 24 weeks of drug treatment with Donepezil Hydrochloride at 5 mg/day, 10 mg/day, and placebo. The graph includes error bars representing the standard error, indicating clinical improvement or decline compared to baseline.*

FDA Label Image

Figure2 (Figure2)

A cumulative percentage of patients graph showing change from baseline in ADAS cognitive scores for Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The x-axis represents change from baseline scores, while the y-axis shows cumulative percentage of patients. The chart includes a legend and a small table of treatment group percentages for changes of -7, -4, and 0 points.*

FDA Label Image

Figure3 (Figure3)

A bar graph comparing the CIBIC-Plus ratings of Donepezil Hydrochloride tablets at 10 mg and 5 mg dosages versus placebo. The x-axis shows categories from markedly improved to markedly worse, while the y-axis shows the percentage of patients in each category.*

FDA Label Image

Figure4 (Figure4)

A line graph showing changes in ADAS-cog score from baseline over 15 weeks of treatment for Donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The y-axis ranges from clinical decline to clinical improvement, with error bars indicating variability at each time point.*

FDA Label Image

Figure5 (Figure5)

A cumulative percentage of patients chart showing cognitive change from baseline on ADAS-cog scale comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The x-axis represents change from baseline scores, with markers at 7 points, 4 points, and no change. The y-axis shows cumulative percentage of patients. Donepezil 10 mg/day shows the highest improvement.*

FDA Label Image

Figure6 (Figure6)

A bar chart depicting the percentage of patients by CIBIC-plus Rating categories comparing Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The x-axis shows ratings from Markedly Improved to Markedly Worse, while the y-axis represents the percentage of patients. Different colored bars represent the three groups.*

FDA Label Image

Figure7 (Figure7)

Line graph depicting the SIB (Severe Impairment Battery) score change from baseline over 6 months of drug treatment comparing Donepezil Hydrochloride 10 mg/day and placebo. The Donepezil group shows clinical improvement, while the placebo group trends toward clinical decline over time.*

FDA Label Image

Figure9 (Figure9)

A line graph showing the mean change from baseline in ADCS-ADL scores over 6 months of drug treatment. The graph compares Donepezil Hydrochloride 10 mg/day and placebo, illustrating clinical improvement versus decline over time with error bars representing standard error.*

FDA Label Image

Structure (Structure)

Chemical structure of Donepezil hydrochloride, illustrating the molecular arrangement including multiple rings, methoxy groups, and the hydrochloride salt form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.